SNCA and synucleinopathy: While reduction of extracellular alpha-synuclein might not be sufficient to influence clinical disease course of PD or related alpha-synucleinopathies, it is critical to develop other strategies to modulate alpha-synuclein expression to understand the effects of different gene dosage levels and to expand the armamentarium of alpha-synuclein regulation for future therapeutic use.